{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:50:40Z","timestamp":1793836240852,"version":"4.6.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,15]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Type I IFN therapies can cause a dose-dependent TMA. Recombinant type I IFN therapies should be stopped at the earliest opportunity in patients who develop TMA.<\/jats:p>","DOI":"10.1182\/blood-2016-05-715987","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T22:58:20Z","timestamp":1474671500000},"page":"2824-2833","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":107,"title":["Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature"],"prefix":"10.1182","volume":"128","author":[{"given":"David","family":"Kavanagh","sequence":"first","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0077-0991","authenticated-orcid":false,"given":"Sarah","family":"McGlasson","sequence":"additional","affiliation":[{"name":"Medical Research Council Institute of Genetics and Molecular Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Jury","sequence":"additional","affiliation":[{"name":"Medical Research Council Institute of Genetics and Molecular Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jac","family":"Williams","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, Edinburgh University, Edinburgh, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Scolding","sequence":"additional","affiliation":[{"name":"Institute of Clinical Neurosciences, University of Bristol, Bristol, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bellamy","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University of Edinburgh, Edinburgh, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gunther","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Technical University Dresden, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, Edinburgh University, Edinburgh, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Gale","sequence":"additional","affiliation":[{"name":"Centre for Nephrology, Royal Free Hospital, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashpal S.","family":"Kanwar","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Challis","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Buist","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Royal Victoria Hospital, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Overell","sequence":"additional","affiliation":[{"name":"Institute of Neurological Sciences, Glasgow University, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Weller","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, Edinburgh University, Edinburgh, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Flossmann","sequence":"additional","affiliation":[{"name":"Royal Berkshire Hospital, Reading, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Blunden","sequence":"additional","affiliation":[{"name":"Barts and the London National Health Service Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krucker","sequence":"additional","affiliation":[{"name":"The Scripps Research Institute, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J. W.","family":"Evans","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain L.","family":"Campbell","sequence":"additional","affiliation":[{"name":"School of Molecular Bioscience, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Medical Research Council Institute of Genetics and Molecular Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharthan","family":"Chandran","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, Edinburgh University, Edinburgh, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-0207","authenticated-orcid":false,"given":"David P. J.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Medical Research Council Institute of Genetics and Molecular Medicine and"},{"name":"Centre for Clinical Brain Sciences, Edinburgh University, Edinburgh, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111902572577800_B1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2019111902572577800_B2","first-page":"1847","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"7140","key":"2019111902572577800_B3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/bmj.316.7140.1295","article-title":"Adverse drug reactions","volume":"316","author":"Pirmohamed","year":"1998","journal-title":"BMJ"},{"issue":"9","key":"2019111902572577800_B4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrneurol.2015.143","article-title":"Type I interferon dysregulation and neurological disease","volume":"11","author":"McGlasson","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"2019111902572577800_B5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00005792-200207000-00008","article-title":"Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature","volume":"81","author":"Zuber","year":"2002","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"2019111902572577800_B6","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","author":"Hunt","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111902572577800_B7","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1177\/1352458514523692","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon \u03b2","volume":"20","author":"Larochelle","year":"2014","journal-title":"Mult Scler"},{"issue":"5","key":"2019111902572577800_B8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12325-015-0212-6","article-title":"Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome reports with subcutaneous interferon \u03b2-1a","volume":"32","author":"Ben-Amor","year":"2015","journal-title":"Adv Ther"},{"issue":"6","key":"2019111902572577800_B9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00002018-200225060-00012","article-title":"Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria","volume":"25","author":"Shakir","year":"2002","journal-title":"Drug Saf"},{"issue":"5","key":"2019111902572577800_B10","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"issue":"3","key":"2019111902572577800_B11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2004.06.003","article-title":"Intravenous immunoglobulin and the kidney--a two-edged sword","volume":"34","author":"Orbach","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"2019111902572577800_B12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111902572577800_B13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome\u2014the first year's experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"},{"issue":"D1","key":"2019111902572577800_B14","doi-asserted-by":"crossref","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","article-title":"INTERFEROME v2.0: an updated database of annotated interferon-regulated genes","volume":"41","author":"Rusinova","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2019111902572577800_B15","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4049\/jimmunol.178.2.1122","article-title":"Identification of genes selectively regulated by IFNs in endothelial cells","volume":"178","author":"Indraccolo","year":"2007","journal-title":"J Immunol"},{"issue":"9","key":"2019111902572577800_B16","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.4049\/jimmunol.161.9.5016","article-title":"Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration","volume":"161","author":"Akwa","year":"1998","journal-title":"J Immunol"},{"issue":"5167","key":"2019111902572577800_B17","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1126\/science.8009221","article-title":"Functional role of type I and type II interferons in antiviral defense","volume":"264","author":"M\u00fcller","year":"1994","journal-title":"Science"},{"issue":"7","key":"2019111902572577800_B18","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1523\/JNEUROSCI.2830-13.2014","article-title":"Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain","volume":"34","author":"Campbell","year":"2014","journal-title":"J Neurosci"},{"issue":"3","key":"2019111902572577800_B19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1523\/JNEUROSCI.3711-09.2010","article-title":"The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9","volume":"30","author":"Hofer","year":"2010","journal-title":"J Neurosci"},{"issue":"9","key":"2019111902572577800_B20","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1073\/pnas.0709788105","article-title":"Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer\u2019s disease","volume":"105","author":"Meyer","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111902572577800_B21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"24","key":"2019111902572577800_B22","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2019111902572577800_B23","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1182\/blood-2014-10-609073","article-title":"Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome","volume":"125","author":"Schramm","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111902572577800_B24","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111902572577800_B25","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","article-title":"Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome","volume":"111","author":"Fang","year":"2008","journal-title":"Blood"},{"key":"2019111902572577800_B26","author":"McDowell"},{"issue":"7","key":"2019111902572577800_B27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri3850","article-title":"Aicardi-Gouti\u00e8res syndrome and the type I interferonopathies","volume":"15","author":"Crow","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2019111902572577800_B28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","article-title":"Assessment of interferon-related biomarkers in Aicardi-Gouti\u00e8res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study","volume":"12","author":"Rice","year":"2013","journal-title":"Lancet Neurol"},{"issue":"5","key":"2019111902572577800_B29","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111902572577800_B30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/01.ede.0000113273.14807.53","article-title":"Incidence of thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome","volume":"15","author":"Miller","year":"2004","journal-title":"Epidemiology"},{"key":"2019111902572577800_B31"},{"key":"2019111902572577800_B32"},{"issue":"9139","key":"2019111902572577800_B33","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"Ebers","year":"1998","journal-title":"Lancet"},{"issue":"suppl 1","key":"2019111902572577800_B34","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2105\/AJPH.2004.059204","article-title":"Causation and causal inference in epidemiology","volume":"95","author":"Rothman","year":"2005","journal-title":"Am J Public Health"},{"issue":"3","key":"2019111902572577800_B35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.msard.2013.12.007","article-title":"Thrombotic microangiopathy in interferon beta treated multiple sclerosis patients: review of literature and report of two new cases","volume":"3","author":"Vosoughi","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"2019111902572577800_B36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/jhh.2013.91","article-title":"Malignant hypertension and interferon-beta: a case report","volume":"28","author":"Rubin","year":"2014","journal-title":"J Hum Hypertens"},{"issue":"6","key":"2019111902572577800_B37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"issue":"8","key":"2019111902572577800_B38","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1600-0560.2007.00900.x","article-title":"Cutaneous histopathological findings of Aicardi-Gouti\u00e8res syndrome, overlap with chilblain lupus","volume":"35","author":"Kolivras","year":"2008","journal-title":"J Cutan Pathol"},{"issue":"1","key":"2019111902572577800_B39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-2004-830532","article-title":"Cerebral thrombotic microangiopathy and antiphospholipid antibodies in Aicardi-Goutieres syndrome--report of two sisters","volume":"36","author":"Rasmussen","year":"2005","journal-title":"Neuropediatrics"},{"key":"2019111902572577800_B40","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2019111902572577800_B41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2990.2002.00406.x","article-title":"The neuropathology and pathogenesis of systemic lupus erythematosus","volume":"28","author":"Scolding","year":"2002","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2019111902572577800_B42"},{"issue":"1","key":"2019111902572577800_B43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/24\/2824\/1358090\/blood715987.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/24\/2824\/1358090\/blood715987.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T03:07:41Z","timestamp":1692500861000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/24\/2824\/35978\/Type-I-interferon-causes-thrombotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":43,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-05-715987","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726771118.793565325","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]}}}